Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Research & Development: 2016-2024

Historic Research & Development for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $138.1 million.

  • Protagonist Therapeutics' Research & Development rose 11.21% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.8 million, marking a year-over-year increase of 11.89%. This contributed to the annual value of $138.1 million for FY2024, which is 14.95% up from last year.
  • As of FY2024, Protagonist Therapeutics' Research & Development stood at $138.1 million, which was up 14.95% from $120.2 million recorded in FY2023.
  • Protagonist Therapeutics' 5-year Research & Development high stood at $138.1 million for FY2024, and its period low was $74.5 million during FY2020.
  • For the 3-year period, Protagonist Therapeutics' Research & Development averaged around $128.2 million, with its median value being $126.2 million (2022).
  • Its Research & Development has fluctuated over the past 5 years, first spiked by 69.12% in 2021, then declined by 4.80% in 2023.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Research & Development stood at $74.5 million in 2020, then skyrocketed by 69.12% to $126.0 million in 2021, then rose by 0.17% to $126.2 million in 2022, then dropped by 4.80% to $120.2 million in 2023, then climbed by 14.95% to $138.1 million in 2024.